Small Pharmaceuticals
Market Cap
₹15,404 ₹15,404 Cr.
P/E
13.46
PEG
4.34
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Base-case growth is driven by 2–3 successful Para IV exclusivity launches and steady scaling in Brazil/Adcock, recovering from the FY27 Revlimid trough.

Bull case triggers if 3+ sole‑FTF exclusivities materialize and Semaglutide US advances, accelerating the earnings bridge well above the base path.

Bear case materializes when Para IV approvals stall >12 months and US pricing intensifies, keeping revenue near the post‑Revlimid floor and delaying margin recovery.

Get your Reports on Demand
Get detailed, analyst-grade reports with actionable insights to make informed investment decisions.
  Flat 20% OFF
 for Tijori Premium Users
  Flat 20% OFF  for Tijori Premium Users
5Y Revenue & EBITDA Estimates
KEY TRIGGERS TO WATCH
  • Base-case growth is driven by 2–3 successful Para IV exclusivity launches and steady scaling in Brazil/Adcock, recovering from the FY27 Revlimid trough.
  • Bull case triggers if 3+ sole‑FTF exclusivities materialize and Semaglutide US advances, accelerating the earnings bridge well above the base path.
  • Bear case materializes when Para IV approvals stall >12 months and US pricing intensifies, keeping revenue near the post‑Revlimid floor and delaying margin recovery.
Bear : 7% CAGR • ₹1,076 Cr
Base: 18% CAGR • ₹1,734 Cr
Bull: 27% CAGR • ₹2,570 Cr
Buy Report $5
Management Credibility Report
TRACK RECORD
  • Management consistently delivers on PAT guidance (treat as a conservative floor) and specific product launch milestones like Semaglutide India.
  • Revenue growth targets are systematically over-optimistic, missing the Revlimid cliff and agro ramp-up; apply a 30–50% discount to top-line and diversification narratives.
  • The credibility gap is concentrated in short‑term revenue forecasting, while long‑cycle pipeline execution and profitability discipline remain reliable.
Met : 10
Progress: 1
Missed : 9
Buy Report $5
WORST-CASE SCENARIO
  • Single-customer concentration at 65.7% of standalone revenue creates an existential dependency that is declining but remains the most severe structural risk.
  • Post-Revlimid pipeline success hinges on binary FDA and litigation outcomes for Semaglutide and Olaparib; a delay would deepen the earnings valley and test the base-business floor.
  • Balance-sheet resilience (D/E 0.04x, Rs 3,200 Cr cash) and conservative PAT guidance provide downside protection against operational shocks.
High Risk : 1
Medium Risk : 6
Low Risk : 10
Buy Report $5
Powered By
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material